Upstate Active Clinical Trials

Study Title:

Millennium Pharmaceuticals, Inc. Protocol C14012: A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigators Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Upstate Institutional Review Board (IRB) Number:

318702

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Bernard J Poiesz, MD

ClinicalTrials.Gov ID:

NCT01482962

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Patricia M Benz
Phone: 315-464-8253
Email: benzp@upstate.edu

Return to Previous Page || Search Again